Results 71 to 80 of about 5,403 (175)

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar

Pharmaceuticals, 2019
The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin’s lymphoma (NHL), the most common hematological malignancy.
Christos Sachpekidis, David B. Jackson, Theodoros G. Soldatos   +2 more
doaj   +1 more source

Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy

CNS Oncology, 2019
Management of high-grade gliomas (HGGs) remains a complex challenge with an overall poor prognosis despite aggressive multimodal treatment. New translational research has focused on maximizing tumor cell eradication through improved tumor cell targeting ...
Joshua Loya, Charlie Zhang, Emily Cox, Achal S Achrol, Santosh Kesari   +4 more
doaj   +1 more source

Experimental and clinical approaches to a radioimmunotherapy in o

Сибирский онкологический журнал, 2016
Molecular nuclear medicine plays an important role in the diagnosis and therapy of cancer. Radioimmunodetection and radioimmunotherapy (RIT) involve the use of antibodies conjugated with diagnostic or therapeutic radionuclides, respectively.
E. V. Abakushina, D. N. Abakushin, Ju. N. Anohin   +2 more
doaj  

Radioimmunotherapy of Ovarian Cancer

The International Journal of Biological Markers, 1993
Radioimmunotherapy (RIT) is a new therapeutical approach where radiolabeled monoclonal antibodies (MAb) against tumor-associated antigens are administered to treat tumor lesions. Ovarian cancer is one of the most promising fields for RIT. This paper gives an overview of some biodistribution studies in animal models and in patients with radiolabeled ...
openaire   +2 more sources

Targeting Cancer Stem Cells with Radioimmunotherapy: The Case of the Ovarian Cancer Stemness-Associated Biomarker L1CAM

International Journal of Translational Medicine
Cancer stem cells (CSCs) are a dynamic population of tumor cells characterized by long-term self-renewal, high tumorigenicity, resistance to conventional therapies such as radio- and chemotherapy, and capacity to recapitulate the tumor heterogeneity ...
Tihomir Zh. Todorov, Roger Schibli, Martin Béhé, Jürgen Grünberg   +3 more
doaj   +1 more source

Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma

Exploration of Targeted Anti-tumor Therapy
Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventional treatment.
Hiroki Goto, Yoshioki Shiraishi, Seiji Okada   +2 more
doaj   +1 more source

Optimizing Cancer Treatment: Exploring the Role of AI in Radioimmunotherapy

Diagnostics
Radioimmunotherapy (RIT) is a novel cancer treatment that combines radiotherapy and immunotherapy to precisely target tumor antigens using monoclonal antibodies conjugated with radioactive isotopes.
Hossein Azadinejad, Mohammad Farhadi Rad, Ahmad Shariftabrizi, Arman Rahmim, Hamid Abdollahi   +4 more
doaj   +1 more source

CD20-Targeted α-Radionuclides Synergize with Immune Checkpoint Inhibition to Treat Murine Lymphoma. [PDF]

J Nucl Med
O'Steen S, Lee SY, Comstock ML, Kehret AR, Lin Y, Hamlin DK, Dexter SL, Hippe DS, Gooley TA, Wilbur DS, Li Y, Walter RB, Till B, Orozco JJ, Green DJ.   +14 more
europepmc   +1 more source

Radioimmunotherapy [PDF]

, 2020
openaire   +1 more source

Development and validation of nomograms integrating electrolyte, nutritional, and inflammatory indicators to predict survival in advanced esophageal cancer undergoing immunotherapy or radioimmunotherapy. [PDF]

J Thorac Dis
Tang S, Feng C, Liang N, Qiao L, Lu Z, Lv Y, Yang X, Hao Y, Zhang J.   +8 more
europepmc   +1 more source